Close

UPDATE: Goldman Sachs Downgrades 10X Genomics (TXG) to Sell

Go back to UPDATE: Goldman Sachs Downgrades 10X Genomics (TXG) to Sell

10x Genomics Offerings Not Yet Big Enough to Offset Core Business Deceleration - GS

August 18, 2022 3:21 PM EDT

Goldman Sachs analyst Matthew Sykes downgraded shares of 10x Genomics (NASDAQ: TXG) to Sell from Neutral in a note Thursday, lowering the price target to $35 from $55.

The analyst said they expect a "materially slower cadence" to the company's 2023/24 sales growth rate vs consensus (and historically) as it transitions to a... More